ELOCTATE®the
only FVIII powered
by Fc Fusion

ELOCTATE®
the only FVIII
powered by Fc
Fusion

Extended Half-life

With Fc Fusion, ELOCTATE stays in circulation 1.5x longer than ADVATE®1

Mean Factor VIII Profile After a Single Dose (50 IU/kg) in Adults (n=28)2

Eloctate stays in circulation 1.5x longer than Advate, 19.7 hours mean terminal half‐life Eloctate stays in circulation 1.5x longer than Advate, 19.7 hours mean terminal half‐life
  • 16.4-hour mean terminal half-life for adolescents1
  • 12.7-hour mean terminal half-life for patients 1 to 5 years old1
  • 14.9-hour mean terminal half-life for patients 6 to 11 years old1

Other PK parameters

  • In A-LONG, the PK profile of 28 patients on ELOCTATE obtained at Week 14 was comparable with its PK profile obtained after the first dose1
  • Additionally, FVIII activity reached its maximum level (Cmax) within an hour of ELOCTATE administration3*

*As demonstrated in a phase 1/2a study of adults with hemophilia A.

Fc=fragment crystallizable; FVIII=factor VIII; PK=pharmacokinetic.

With Fc Fusion, ELOCTATE stays in circulation 1.5x longer than ADVATE®1

Mean Factor VIII Profile After a Single Dose (50 IU/kg) in Adults (n=28)2

Mean Factor Chart_revised_ArtboardMean Factor Chart_revised_Artboard
circle-data
  • 16.4-hour terminal half-life for adolescents1
  • 12.7-hour terminal half-life for patients 1 to 5 years old, and 14.9 hours for patients 6 to 11 years old1
  • In A-LONG, the PK profile of 28 patients on ELOCTATE obtained at Week 14 was comparable with its PK profile obtained after the first dose1

ADVATE® [Antihemophilic Factor (Recombinant)] is a registered trademark of Baxalta Incorporated, a Takeda company.

PK=pharmacokinetic.

Fc Fusion helps ELOCTATE stay in circulation through a natural pathway and does not accumulate1,3

ELOCTATE contains the Fc region of IgG11

IgG1 allows ELOCTATE to extend its half-life by binding to the neonatal Fc receptor1

IgG1 is a naturally occurring protein that has anti-inflammatory and immunomodulatory properties1,4,5

The molecular mechanism behind the effects achieved by ELOCTATE is not
yet fully understood, including the interaction with cellular Fc receptors that ELOCTATE
may interact with, such as on immune cells5

Poly vector 4,-d-,1-01

Fc Fusion helps ELOCTATE stay in circulation through a natural pathway and does not accumulate1,4

Sanofi Logo

This site is intended for United States Residents only.

© 2022 Genzyme Corporation. All rights reserved.

ELOCTATE and Sanofi are registered trademarks of Sanofi or an affiliate. MyELOCTATE is owned by Genzyme Corporation.
All the other trademarks above are the property of their respective owners, who have no affiliation or relationship with Sanofi.

MAT-US-2003082-v5.0-03/2022 Last Updated: March 2022